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Abstract 
Purpose: To evaluate the effect of lysophosphatidic acid (LPA) on the proliferation, invasion and 
migration ability of 3AO, SKOV3 and CAOV3 human ovarian cancer cell lines.  
Methods: SKOV3, 3AO and CAOV3 cell lines were respectively treated with LPA. Changes in the 
proliferation rate of these cell lines were observed after LPA treatment. The cell lines that were not 
treated with LPA served as control group. Boyden chamber was used to assess cell invasion and 
migration capability. The expression levels of relevant cytokines related to cell migration in the 
supernatant of CAOV3 cell line were determined using ELISA following LPA stimulation.  
Results: The cell proliferation rate of human ovarian cancer cell lines was significantly accelerated after 
in vitro LPA treatment in a concentration-dependent fashion. Boyden chamber assay data indicate that 
invasion indices in 3AO and CAOV3 cell lines were significantly higher than those in untreated control 
cell lines (p < 0.05). However, no statistical significance was noted between 3AO and CAOV3 cell lines 
(p < 0.05). The expression levels of relevant cytokines in the CAOV3 cell line were significantly up-
regulated after LPA treatment (p < 0.05).  
Conclusion: LPA intervention in vitro accelerates cell proliferation rate and also significantly up-
regulates the expression levels of multiple cytokines related to cell migration in human ovarian cancer 
cell lines, suggesting that LPA plays a significant role in the invasion and migration of SKOV3, 3AO and 
CAOV3 cell lines.  
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Lysophosphatidic acid (LPA) is a bioactive lipid 
mediator involved in tissue repair and wound 
healing. It mediates diverse functional effects in 
fibroblasts, including proliferation, migration and 
contraction, but less is known about its ability to 
evoke paracrine signaling to other cell types. In 
recent years, LPA and its receptor signaling 
pathways have been shown to be implicated in 
the incidence, invasion and migration processes 
of malignant tumors [1-6].  
 
Ovarian cancer is a highly metastatic disease 
which is characterized by ascites formation and 
adhesion, invasion, and metastasis. Levels of 
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LPA are significantly increased in the plasma of 
ovarian carcinoma patients, indicating that LPA 
can promote the incidence of early events in 
ovarian carcinoma dissemination. LPA is capable 
of playing a role via its receptors. LPA receptors 
belong to the endothelial differentiation gene 
(Edg) family, which consists of 4 categories. In 
particular, LPA1/Edg-2, LPA2/Edg-4 and 
LPA3/Edg-7 are frequently investigated.  
 
Recent studies [1,3] have demonstrated that G 
protein-coupled receptor 23 (GPR23)/p2y9/LPA4 
is lowly expressed in the ovarian tissues of most 
healthy subjects. However, Edg-4 and Edg-7 are 
highly expressed in human ovarian cancer cell 
lines. LPA is able of accelerating DNA synthesis 
after binding with Edg-4 and Edg-7. LPA has 
been identified to regulate the proliferation, 
migration and adhesion of cancer cells, the 
release and activation of matrix metalloproteinase 
(MMP) and the secretion of angiogenesis factors 
[7-9], indicating that LPA plays a pivotal role in 
the invasion and metastasis processes of 
malignant tumor cells.  
 
In this study, human ovarian cancer cell lines 
including 3AO, CAOV3 and SKOV3 were 
selected and treated with different concentrations 
of LPA. Subsequently, the growth, proliferation, 
invasion and metastasis ability of the ovarian 
cancer cells were evaluated after LPA treatment. 
The expression levels of multiple cytokines 
related to cellular invasion and migration were 




MTT assay   
 
The effect of LPA upon the growth and 
proliferation of ovarian cancer cell lines was 
assessed by MTT assay. The ovarian cancer cell 
lines 3AO, SKOV3 and CAOV3 were cultured in 
RPMI1640 complete culture solution containing 10 
% fetal bovine serum at 37 ℃ and 5 % CO2. The 
ovarian cancer cell lines were inoculated for 24 h 
and serum-free culture solution was 
supplemented overnight. The obtained cell lines 
were inoculated in a 96-well plate at a cell density 
of 5×103/well, cultured for 24 h using conventional 
method and co-cultured with different 
concentrations of LPA (0.2,2,10 and 20 µmol/L). 
 
The culture solution was abandoned at 2, 4, 6, 16 
and 24 h after LPA supplement, a portion of 20 
mL MTT solution at a concentration of 5 µg/µL 
was added in each well, continuously cultured for 
4 h, and 150 mL DMSO was supplemented in 
each well. The absorbance value of each well was 
measured at a wavelength of 490 and 620 nm. 
The cell growth curve was drawn. The cell 
proliferation rate = (Absorbance value LPA group-
absorbance value control group)/absorbance value 
control group×100 %. Three replicates were set for 
each concentration in each well. In the control 
group, LPA was substituted with the PBS. 
 
Boyden chamber assay  
 
The ovarian cancer cell lines 3AO and CAOV3 
were cultured in RPMI1640 complete culture 
solution containing 10 % fetal bovine serum. In 
the LPA group, 5 and 20 µmol/L of LPA was 
added and PBS was used in the control group for 
16 h. The obtained cells in logarithmic phase were 
digested in 0.25% pancreatin and a portion of 80 
µL suspension containing 2 × 106 of cells was 
prepared. Artificial matrix gel matrige1 (BD 
corporation, U.S.) was smeared on polycarbonate 
millipore filter (Waltman, U.S.) approximately 150 
µg for each well and maintained at 37 ℃ for 3 h, 
air dried at room temperature overnight.  
 
A portion of 20 µL serum-free solution was added 
in the lower Boyden chamber and pretreated cell 
suspension was added in these upper Boyden 
chamber. The obtained cells were cultured at 37 
℃ and 5 % CO2 for 18 h, fixed in 70 % methanol 
for 45 min, stained in hematoxylin for 1 - 2 min, 
washed triple times using distilled water, 
transferred on to a slide, sealed with a cover slip 
and observed under high-power light microscope. 
Three replicates were set for each concentration 
in each well. In the control group, LPA was 
substituted with PBS. 
 
Cytokine detection after LPA treatment 
 
The CAOV3 cell line was cultured in serum-free 
solution for 12 h and treated with different 
concentrations of LPA (5, 20 and 40 µmol/L) for 
16 h, and LPA was replaced by PBS in the 
control group. The treated cells in logarithmic 
growth phase were digested using 0.25 % 
pancreatin containing 10 % fetal bovine serum, 
transferred into the centrifuge tube and added by 
100 µL culture solution. The cell suspension at a 
density of 2 × 106/mL was prepared using 0.9 % 
cell suspension and the supernatant was 
preserved at -80 oC. 
 
After LPA treatment at a concentration of (0, 5, 20 
and 40 µL/L),  CXCL12 (C-X-C motif ligand12), E-
cadherin, vascular endothelial growth factor 
(VEGF), vascular endothelial growth factor 
receptor (VEGFR), epidermal growth factor 
(EGF), epidermal growth factor receptor (EGFR) 
were quantitatively measured  using ELISA (R & 
D Systems Inc.). The experimental procedures 
were performed strictly according to the 
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manufacturer's instructions. Three replicates were 
set for each concentration in each well. In the 




SPSS19.0 statistical software was used for 
statistical analysis and the data are expressed as 
mean ± standard deviation (SD). Replicate data 
were statistically analyzed by ANOVA. Group 
comparison was performed by LSD test. P < 0.05 




Effect of LPA treatment upon ovarian cancer 
cell growth and proliferation  
 
The cell lines were treated with different 
concentrations of LPA, the absorbance values in 
the LPA group were significantly higher 
compared with those in the control group. At 10 
µmol/L LPA treatment for 16 h, the proliferation 
rate of 3AO, SKOV3 and CAOV3 cell lines was 
significantly enhanced compared with that in the 
control group, as illustrated in Figure 1. 
 
Effect of LPA upon ovarian cancer cell 
invasion  
 
The outcome of cell invasion did not significantly 
differ between the 3AO and CAOV3 cell lines 
treated with PBS, 5 and 20 µmol/L LPA (χ2 = 
3.648, p = 0.052; χ2 = 3.283, p = 0.056; χ2 = 3.431, 
p = 0.054). In the 3AO and CAOV3 cell lines, the 
invasion ability was significantly increased after 5 
and 20 µmol/L treatment (χ2 = 4.355, p = 0.029; χ2 
= 4.170, p = 0.012). Statistical significance was 
also observed between the 5 and 20 µmol/L 
intervention groups (χ2 = 4.288, p = 0.037), as 
illustrated in Figure 2 and Table 1. The invasion 
ability was positively correlated with increasing 
LPA concentration. 
 
Table 1: Effect of different concentrations of LPA on 




Invasion capability  
3AO CAOV3 
Blank control  23.5 ± 1.1 22.8 ± 1.2 
5 μmol/L LPA 25.7 ± 1.3^ 24.8 ± 0.7^ 
20 μmol/L LPA 30.4 ± 1.7*# 29.2 ± 1.1*# 
Note: *χ2 = 4.355, p = 0.029 compared with the blank 
control group; #χ2 = 4.170, p = 0.043 compared with the 
blank control group; ^χ2 = 4.221, p = 0.037 compared 
with the 5 μmol/L LPA group 
 
Effect of LPA on expression levels of multiple 
cytokines 
 
The expression levels of CXCL12, E-cadherin, 
VEGF, VEGFR, EGF and EGFR in the CAOV3 
cell supernatant after 5, 20 and 40 µmol/L 




Figure 1: Effect of different concentrations of LPA on the proliferation rates of 3AO (A), SKOV3 (B) and CAOV3 




Figure 2: Morphological effect of LPA on the invasion capability of CAOV3 cells by Boyden chamber assay (× 
200) in the control (A), 5 μmol/L (B) and 20 μmol/L (C) of LPA 
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CXCL12 (µmol / L) 2.21 ± 1.01 1.65 ± 0.32 1.51 ± 0.05 1.48 ± 0.14 1.733 0.055 
VEGF (ng / mL) 1.12 ± 0.05 1.15 ± 0.02 1.15 ± 0.05 1.18 ± 0.03 5.022 0.002 
VEGFR (nmol / L) 70.25 ± 4.23 100.02 ± 0.03 100.04 ± 0.03 100.05 ± 0.01 5.002 0.011 
EGF (pg/mL) 39.55 ± 4.42 41.25 ± 1.25 37.20 ± 0.00 39.59 ± 0.02 5.688 0.005 
EGFR (ng / mL) 1.82 ± 0.24 1.55 ± 0.24 1.48 ± 0.45 1.51 ± 0.04 1.755 0.188 
E-cadherin (pmol / L) 13.33 ± 1.21 12.95 ± 4.21 19.88 ± 0.48 23.21 ± 9.21 4.002 0.015 
 
statistical significance was observed of the 
CXCL12 expression level between the control 
and the LPA treatment groups (F = 1.738, p = 
0.052). The expression level of E-cadherin 
significantly differed between the control and LPA 
treatment groups (F = 4.073, p = 0.021). 
Statistical significance was observed in E-
cadherin level among different concentrations of 
the LPA groups (p = 0.004).  
 
The expression level of E-cadherin was 
significantly up-regulated along with increasing 
concentration of LPA. In the LPA intervention 
group, the expression level of VEGF ranged from 
1.08 to 1.19 ng/mL with a median value of 1.14 
ng/mL, significantly higher compared with that in 
the control group (F = 5.032, p = 0.002). The 
expression levels of VEGF did not significantly 
differ among different LPA concentration groups. 
Nevertheless, the expression level increased 
along with elevation of LPA concentration. The 
expression levels of VEGFR in the different LPA 
concentration groups were all significantly up-
regulated compared with that in the control group 
(F = 5.000, p = 0.010), whereas no statistical 
significance was observed among different LPA 
concentration groups. 
 
The expression levels of EGF significantly 
differed between the control and LPA treatment 
groups (F = 5.678, p = 0.006), whereas no 
statistical significance was observed among 
different LPA concentration groups (all p > 0.05). 
EGF expression significantly differed between the 
5 and 20 µmol/L treatment groups (p = 0.001). No 
statistical significance was observed between the 
5 and 40 µmol/L groups (p = 0.055) in terms of 
the EGF expression level.  
 
Statistical significance was observed between the 
20 and 40 µmo1/L LPA groups (p = 0.000), 
suggesting that the expression of EGF showed a 
dose-dependent fashion. No statistical 
significance was observed in the EGFR 
expression levels between the LPA treatment and 
control groups or among different LPA 





Previous studies have demonstrated that LPA 
receptor is expressed in the human ovarian 
cancer cell lines 3AO, SKOV3 and CAOV3 [9]. 
LPA possesses multiple biological functions 
through LPA receptors located on the cell 
membrane. LPA has been shown to play a vital 
role in the invasion and migration of malignant 
tumor cells. The findings in this study further 
demonstrate that LPA administration is able to 
enhance the proliferation of ovarian cancer cells, 
which is consistent with previous investigations 
[10].  
 
Boyden chamber experiment revealed that the 
invasion capability of 3AO and CAOV3 cell lines 
was significantly increased after LPA treatment, 
which was significantly higher compared with that 
in the control group. In addition, the invasion 
ability of ovarian cancer cells was positively 
correlated with increasing concentration of LPA 
administration. However, no statistical 
significance was observed in the cell invasion 
between 3AO and CAOV3 cell lines.  
 
The results of this investigation indicate that LPA 
is capable of binding with tumor cell surface 
receptors to participate in the growth, proliferation 
and migration of malignant tumor cells. The 
supernatant solution of the ovarian cancer cell 
suspension was collected and demonstrated that 
LPA can stimulate the growth of CAOV3 cell line 
and significantly up-regulate the expression level 
of CXCL12 cytokines. These findings collectively 
suggest that CAOV3 cell line is able to secrete a 
certain quantity of CXCL12, which is capable of 
binding with CXCR4 to induce the formation of 
actin-related pseudopod and regulate the 
directional migration, invasion and angiogenesis 
of tumor cells. CXCL12 is highly expressed in the 
ascites of ovarian cancer patients, suggesting 
that CXCLl2/CXCR4 probably plays a role in the 
metastasis of ovarian cancer. Statistical analysis 
revealed statistical significance in the E-cadherin 
expression level in the supernatant after 
corresponding LPA treatment. The expression 
level of E-cadherin was significantly up-regulated 
along with increasing concentration of LPA 
administration, indicating that E-cadherin 
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expression is positively correlated with LPA 
concentration, thereby affecting cancer cell 
formation. Moreover, LPA treatment can affect 
the adaptability of tumor cells towards external 
environment, which potentially increases the 
resistance ability of cancer cells towards 
chemotherapeutic agents. 
Similarly, the expression level of VEGF in the 
supernatant of ovarian cancer cell line was also 
positively correlated with increasing concentration 
of LPA treatment. VEGF is a pivotal signaling 
protein involved in both vasculogenesis, and 
angiogenesis. The activity of VEGF is restricted 
mainly to the vascular endothelial cells, although 
it exerts effects upon a limited quantity of other 
cell types, such as stimulation 
monocyte/macrophage migration. In vitro 
experiment demonstrates that VEGF can 
stimulate endothelial cell mitogenesis and cell 
migration. VEGF also enhances microvascular 
permeability and is occasionally referred as 
vascular permeability factor. The increase in 
VEGF concentration can up-regulate the 
expression level of VEGFR, which is considered a 
vital mechanism underlying the effect of VEGF on 
the promotion of angiogenesis of tumor tissues 
[11].  
 
The expression level of VEGFR in the LPA 
treatment group was significantly up-regulated 
compared with that in the control group, whereas 
no statistical significance was observed among 
different LPA concentration groups. The CAOV3 
cancer cells can secrete VEGFR via autocrine or 
paracrine pathway, which migrate into ascites or 
extracellular space. The interaction between 
VEGF and VEGFR is capable of provoking the 
migration of ovarian cancer cells.  
 
Similarly, the expression level of EGF in the LPA 
treatment group was significantly up-regulated 
compared with that in the control group. In 
addition, the expression level of EGF was 
increasingly up-regulated along with increasing 
concentration of LPA, which peaked at 20 µmol/L 
and subsequently began to decline. The 
expression level of EGF after 20 µmol/L LPA 
treatment was significantly higher compared with 
that following 40 µmol/L LPA treatment. Although 
the expression level of EGFR is regulated by the 
LPA in a concentration-dependent manner, no 
statistical significance was detected among 
different LPA concentration groups, which is 
consistent with our previous findings that the 
expression level of EGFR is low in the chylous 
ascites of ovarian cancer patients, suggesting 
that LPA exerts no significant effect upon the 
production of EGFR by ovarian cancer cells.  
 
The experimental results in this investigation 
revealed that LPA exerts a nonsynchronous effect 
upon the production of EGF and EGFR. Previous 
investigations have demonstrated that CXCLl2 
can stimulate the growth and proliferation of 
ovarian cancer cells through mediating the EGFR 
[12]. Though the content of soluble EGFR is 
relatively low, the biological role of EGFR should 
be emphasized. The role of EGF-EGFR 
interaction in the invasion and metastasis of 
ovarian cancer remains to be elucidated. 
 
In this investigation, LPA exerts different effects 
on CXCL12, VEGF and their receptors, whereas 
it does not affect the level of CXCLl2 secreted by 
ovarian cancer cells. However, LPA exerts a 
significant effect upon VEGF and VEGFR, 
indicate that blockage of CXCR4/CXCL12 
biological axis can inhibit tumor growth and 
suppress the role of VEGF in vascularization, 
which is consistent with previous reports [13,14]. 
The findings in this investigation may provide 





LPA treatment in vitro enhances cell proliferation 
rate and significantly up-regulates the expression 
levels of multiple cytokines associated with cell 
migration in human ovarian cancer cell lines, 
indicating that LPA plays a significant role in the 
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